Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine with or without hydroxyurea versus hydroxyurea in advanced proliferative chronic myelomonocytic leukemia
2014-000200-10Phase 3Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of decitabine in chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Event-free survival. Started May 2014; status: completed.
02
Drugs
decitabine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2014-000200-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000200-10.